Create account

Coverage dated September 21, 2025

Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Headline from WDIO Duluth

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5-billion acquisition. The COVID-19 vaccine maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera.

WDIO Duluth's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

5 articles, oldest first.

  1. WDIO Duluth

    Pfizer amps up push into obesity treatments with $4.9B deal for Metsera (opens WDIO Duluth)

    Published

    WDIO Duluth's feed description

    Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5-billion acquisition. The COVID-19 vaccine maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera.

  2. MedicalXpress

    Pfizer to acquire obesity-drug maker Metsera for $4.9 bn (opens MedicalXpress)

    Published

    MedicalXpress's feed description

    US pharmaceutical giant Pfizer will acquire Metsera, a maker of drugs for obesity and heart disease, for $4.9 billion, the companies said Monday.

  3. The Boston Globe

    Pfizer amps up push into obesity treatments with $4.9 billion deal for Metsera (opens The Boston Globe)

    Published

    The Boston Globe's feed description

    Pfizer currently has no obesity treatments on the market but has some in clinical development.

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

Pfizer amps up push into obesity treatments with $4.9B deal for Metsera | Since Then